PerkinElmer Signs Exclusive Licensing Agreement with Max Planck Innovation for SiPM Technology
News Aug 21, 2009
PerkinElmer, Inc. has announced that it has entered into an exclusive agreement with Max Planck Innovation, the technology transfer organization of the Max Planck Society, for the licensing of its ultra-fast, low cross-talk solid state silicon photomultiplier (SiPM) technology.
SiPM offers very high photon detection efficiencies, ultra-short response time and extremely low power consumption, making it applicable to a variety of low light level (LLL) applications. The technology was initially developed by a group led by Professor Boris Dolgoshein from the Moscow State Engineering Physics Institute (MEPhI), and further advanced through the cooperation of MEPhI and Professor Masahiro Teshima and Dr. Razmik Mirzoyan from the Max Planck Institute for Physics in Munich.
“This innovative SiPM technology from the Max Planck Society shows promise for several important human and environmental health applications,” said Michael Ersoni, vice president and general manager of PerkinElmer’s global detection business. “This licensing agreement complements and enhances PerkinElmer’s industry-leading portfolio of photon detection solutions. With access to Max Planck’s SiPM technology, PerkinElmer is further positioned to serve applications including positron emission tomography (PET) diagnostic scanning and a variety of analytical fluorescence applications.”
PerkinElmer’s photon detection solutions include Si and InGaAs avalanche photodiodes (APDs) and PIN photodiodes for high performance applications as well as channel photomultipliers for molecular detection in analytical applications and clinical diagnostics.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018